Publications
Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol. 2021;85(5):1274-1284. doi:10.1016/j.jaad.2021.07.054
Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry [published online ahead of print, 2021 Dec 31]. Ann Rheum Dis. 2021;annrheumdis-2021-221490. doi:10.1136/annrheumdis-2021-221490
Dhama K, Patel SK, Natesan S, et al. COVID-19 in the elderly people and advances in vaccination approaches. Hum Vaccin Immunother. 2020;16(12):2938-2943. doi:10.1080/21645515.2020.1842683
Uprety S, Paudel S, Thapa P. Pattern of Skin Diseases in Geriatric Population: Our Year-Long Experience from Nepal. Indian Dermatol Online J. 2021;12(6):888-891. Published 2021 Nov 22. doi:10.4103/idoj.IDOJ_65_21
Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants [published online ahead of print, 2022 Jan 5]. N Engl J Med. 2022;NEJMoa2116597. doi:10.1056/NEJMoa2116597
Liu L, Iketani S, Guo Y, et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2 [published online ahead of print, 2021 Dec 23]. Nature. 2021;10.1038/s41586-021-04388-0. doi:10.1038/s41586-021-04388-0
Piccolo V, Russo T, Mazzatenta C, et al. COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis [published online ahead of print, 2022 Jan 11]. J Eur Acad Dermatol Venereol. 2022;10.1111/jdv.17918. doi:10.1111/jdv.17918
Huang YW, Tsai TF. Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center. Front Med (Lausanne). 2021;8:812010. Published 2021 Dec 23. doi:10.3389/fmed.2021.812010
Wei N, Kresch M, Elbogen E, Lebwohl M. New onset and exacerbation of psoriasis after COVID-19 vaccination. JAAD Case Rep. 2022;19:74-77. doi:10.1016/j.jdcr.2021.11.016
Demiri J, Abdo M, Tsianakas A. Erythroderme Psoriasis nach COVID-19-Erkrankung [Erythrodermic psoriasis after COVID-19] [published online ahead of print, 2021 Dec 14]. Hautarzt. 2021;1-4. doi:10.1007/s00105-021-04931-0
Agarwal A, Tripathy T, Kar BR. Guttate flare in a patient with chronic plaque psoriasis following COVID-19 infection: A case report. J Cosmet Dermatol. 2021;20(10):3064-3065. doi:10.1111/jocd.14396
Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19. N Engl J Med. 2021;385(26):2413-2420. doi:10.1056/NEJMoa2115624
Seror R, Camus M, Salmon JH, et al. Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatol. 2022;4(1):e8-e11. doi:10.1016/S2665-9913(21)00314-3
Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 2022;4(1):e42-e52. doi:10.1016/S2665-9913(21)00333-7
Cristaudo A, Graceffa D, Pimpinelli F, et al. Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs [published online ahead of print, 2021 Dec 11]. J Eur Acad Dermatol Venereol. 2021;10.1111/jdv.17861. doi:10.1111/jdv.17861
This program is supported by educational grants from AbbVie, Amgen, Janssen and UCB.